Sara Ghorashian qualified from Oxford University and undertook haematology training at the Hammersmith and Royal Free Hospitals. She obtained a PhD at University College London (UCL) in the use of gene-engineered T cells for cancer immunotherapy. More recently, her post-doctoral studies at the UCL Great Ormond Street Institute of Child Health involved translation of CD19CAR T cells as therapy for childhood acute lymphoblastic leukaemia (ALL) from bench to bedside. Her research interests are cellular immunotherapy for haematological malignancies and T cell immunobiology.
She has clinical interests in paediatric malignant haematology, and leads on cell therapy and research within the department. She is a co-investigator on two CAR T cell studies for ALL, and actively involved in implementing new studies in order to improve outcomes for children with high risk or relapsed haematological malignancies.
- Paediatric malignant haematology
- Cellular therapy for haematological malignancies
Development and optimisation of cellular therapies for haematological malignancies
- BMBCh - Medicine (Oxford University)
- MA (Hons) – Physiological Sciences (Oxford University)
- MRCP - Royal College of Physicians, London
- PhD – Immunology
- FRCPath – Royal College of Pathologists, London
- Development and optimisation of cellular therapies for haematological malignancies
- T cell immunobiology
News & Publications
Khan AB, Carpenter B, Sousa PSE, Pospori C, Khorshed R, Griffin J, Veliça P, Zech M, Ghorashian S, et. al. Redirection to the bone marrow improves T cell persistence and antitumor functions. J Clin Invest. doi: 10.1172/JCI97454 (epub ahead of print)
Vormittag P, Gunn R, Ghorashian S, Veraitch FS. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol.53:164-181.
Rossig C, Pule M, Altvater B, Saiagh S, Wright G, Ghorashian S., et al. Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia. Leukemia. DOI: 10.1038/leu.2017.39.
Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S., et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Science and Translational Medicine. 9(374). doi: 10.1126/scitranslmed.aaj2013.
Holler A., Zech M., Ghorashian S., Pike R., et al. Expression of a dominant T cell receptor can reduce toxicity and enhance tumour protection of allogeneic T cell therapy. Haematologica, 101(4):482-90.
Ghorashian, S., Pule, M., Amrolia, P. CD 19 chimeric antigen receptor therapy for haematological malignancies. British Journal of Haematology. 169(4), 463-78
Ghorashian, S., Velica, P., Chua, I., McNicol, A-M., et al. CD8 T cell tolerance to a tumour associated self antigen is reversed by CD4 T cells engineered to express the same T cell receptor. Journal of Immunology 194(3), 1080-9
Buchan, S.L., Manzo, T., Flutter, B., Rogel, A., Edwards, N., Zhang, L., Sivakumaran, S., Ghorashian, S., et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ cells to exit quiescence. Journal of Immunology, 194(1), 125-33
Zimbarra Cabrita, I., Abubaker, M., Layton, M., Ghorashian, S., et al. The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom. British Journal of Haematology, 162(3): 400-408.
Xue, S.-A., Gao, L., Ahmadi, M., Ghorashian, S., et al. Human MHC Class I-restricted high avidity CD4+ T cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology 2 (1), e22590
Nicholson, E., Ghorashian, S., & Stauss, H. Improving TCR Gene Therapy for Treatment of Haematological Malignancies. Advances in Hematology, 2012, 404081
Dr Sara Ghorashian Details
Share Dr Sara Ghorashian profile with someone: